Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03604198 · ClinicalTrials.gov registry record · Phase 2
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
A Phase 2 study of Cushing Syndrome, sponsored by Corcept Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
- 20
- Study locations
NCT03604198: Active Phase 2 study of Cushing Syndrome, sponsored by Corcept Therapeutics.
NCT03604198 is a Phase 2 study of Cushing Syndrome that is active but no longer recruiting, run by Corcept Therapeutics. The registered enrollment target is 125 participants, below the 166-participant average among 9 other Cushing Syndrome trials with a reported enrollment target (25% lower). The trial reports 20 study locations across 18 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03604198, a Phase 2 study of Cushing Syndrome, is active but no longer recruiting, sponsored by Corcept Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.
Primary Outcome
Number of patients with treatment-emergent adverse events (TEAEs) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 or higher
Conditions Studied
Interventions
- DRUG relacorilant
Study Locations (20)
California
- Site 35 - Stanford
- Site 39 - Torrance
New York
- Site 6 - Albany
- Site 24 - New York
Arizona
- Site 49 - Phoenix
Florida
- Site 50 - Miami
Georgia
- Site 10 - Atlanta
Illinois
- Site 9 - Chicago
Indiana
- Site 1 - Indianapolis
Louisiana
- Site 5 - Metairie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2018-05-07 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What the registry record for NCT03604198 still lists
NCT03604198 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 166-participant average among 9 other Cushing Syndrome trials with a reported enrollment target (25% lower).
The record links to 1 condition, with Cushing Syndrome appearing as the primary indexed condition, and to 1 intervention - of which relacorilant is the first listed.
NCT03604198 names 20 study sites across 18 states, led by California, New York, Arizona.
Frequently Asked Questions
What is clinical trial NCT03604198 about?
NCT03604198 is a clinical study titled "Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome". This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.
What is the current status of trial NCT03604198?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2018-05-07. Estimated completion is 2026-12.
What conditions does trial NCT03604198 study?
This clinical trial studies the following conditions: Cushing Syndrome.
What interventions are being tested in trial NCT03604198?
The interventions under investigation include: relacorilant (DRUG).
Who is sponsoring clinical trial NCT03604198?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03604198 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cushing Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03604198's enrollment target sits among peer trials
125 5th of 9 higher than 5 of 9 other Cushing Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cushing Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome
RECRUITING · Phase 2
-
Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome
RECRUITING · Phase 2
-
New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome
COMPLETED · Phase 2
-
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
RECRUITING · Phase 1
-
Collecting Information About Treatment Results for Patients With Cushing's Syndrome
RECRUITING
-
Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI